Novo said in March it would initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug. Novo Nordisk‘s hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world’s second-largest economy and the country estimated to hold the highest number of overweight or obese people.